Program
enlicitide decanoate
Also written as “Enlicitide Decanoate”, “Enlicitide decanoate” and “Enclitide Chloride”.
Its studies are mostly in Hypercholesterolemia · Hyperlipoproteinemia Type II · Arteriosclerosis, led by Merck.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 154 open or running | phase 3since Jul 10, 2023 | Feb 22, 2022 | Nov 26, 2027phase 3 · NCT07821944 |
Also a collaborator on its studies: celerion.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 22, 2022First study: phase 2 study in HypercholesterolemiaFirst studyNCT05261126 · 381 enrolled · United States, Germany, Japan and more
- Jun 5, 2023Phase 1 study in HypercholesterolemiaNCT05934292 · 33 enrolled · United States
- Jul 10, 20232 phase 3 studies in HypercholesterolemiaNCT05952869, NCT05952856
- Aug 17, 2023Phase 3 study in ArteriosclerosisNCT06008756 · 14,550 enrolled · United States, Argentina, Australia and more
- Jul 1, 2024Phase 3 study in HypercholesterolemiaNCT06492291 · 3,000 enrolled · United States, Argentina, Australia and more
- Sep 9, 2024Phase 1 study in HypercholesterolemiaNCT06592339 · 24 enrolled · United States
- Oct 1, 20242 phase 1 studies in HealthyNCT06625814, NCT06658652
- Nov 13, 20243 phase 1 studies in HealthyNCT06691906, NCT06699355, NCT06699329
- Jan 9, 2025Phase 1 study in HealthyNCT06772792 · 36 enrolled · United States
- Jul 1, 2025Phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07058077 · 153 planned · United States, Australia, Belgium and more
- Sep 9, 2026Phase 3 study in HyperlipidemiasNCT07821944 · 150 planned · India
Ahead
- Nov 26, 2027Primary completion: phase 3 study in HyperlipidemiasNCT07821944
- Oct 13, 2028Primary completion: phase 3 study in HypercholesterolemiaNCT06492291
- Nov 29, 2029Primary completion: phase 3 study in ArteriosclerosisNCT06008756
- Dec 4, 2033Primary completion: phase 3 study in Heterozygous Familial Hypercholesterolemia (HeFH)NCT07058077
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 15 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07821944Hyperlipidemias · India | 3 | Recruiting | Nov 26, 2027 | 150 |
| NCT07058077Heterozygous Familial Hypercholesterolemia (HeFH) · United States, Australia, Belgium and more | 3 | Recruiting | Dec 4, 2033 | 153 |
| NCT06772792Healthy · United States | 1 | Completed | Jun 21, 2024 | 36 |
| NCT06699355Healthy · United States | 1 | Completed | Dec 29, 2023 | 18 |
| NCT06699329Healthy · United States | 1 | Completed | May 24, 2024 | 38 |
| NCT06691906Healthy · United States | 1 | Completed | May 1, 2024 | 40 |
| NCT06658652Healthy · United States | 1 | Completed | Dec 26, 2023 | 34 |
| NCT06625814Healthy · United States | 1 | Completed | Aug 19, 2024 | 28 |
| NCT06592339Hypercholesterolemia · United States | 1 | Completed | Dec 29, 2022 | 24 |
| NCT06492291Hypercholesterolemia · United States, Argentina, Australia and more | 3 | Active, not recruiting | Oct 13, 2028 | 3,000 |
| NCT06008756Arteriosclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Nov 29, 2029 | 14,550 |
| NCT05952869Hypercholesterolemia · United States, Australia, Brazil and more | 3 | Completed | Apr 7, 2025 | 303 |
| NCT05952856Hypercholesterolemia · United States, Argentina, China and more | 3 | Completed | Jul 28, 2025 | 2,912 |
| NCT05934292Hypercholesterolemia · United States | 1 | Completed | Jan 19, 2024 | 33 |
| NCT05261126Hypercholesterolemia · United States, Germany, Japan and more | 2 | Completed | Nov 28, 2022 | 381 |
How it is read
Names in the registry
- “Enlicitide Decanoate”, 11 entries
- “Enlicitide decanoate”, 2 entries
- “Enclitide Chloride”, 1 entry
- “MK-0616”, 1 entry
Conditions, from the studies’ own filings
- Hypercholesterolemia, 7 studies
- Hyperlipoproteinemia Type II, 1 study
- Arteriosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.